|
|
|
|
|
|
Sponsored by: |
Cura Biotech LLC |
Information provided by: | Cura Biotech LLC |
ClinicalTrials.gov Identifier: | NCT00455208 |
The purpose of the study is to evaluate the safety and efficacy of Cura-100 in treating rheumatoid arthritis and osteoarthritis.
Condition | Intervention | Phase |
Rheumatoid Arthritis Osteoarthritis |
Drug: Cura-100 |
Phase I Phase II |
MedlinePlus related topics: | Osteoarthritis Rheumatoid Arthritis |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis |
Estimated Enrollment: | 20 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | December 2008 |
This is the Phase I/II trial, which monitors both safety and efficacy of Cura-100 in subjects with rheumatoid arthritis and osteoarthritis at one clinical study center. The open-label clinical study will be used in the study. The study is expected to last for one and a half year after it has been officially started, which include recruitment, study treatment and follow-ups. The healthy volunteers are also included to study the safety of the intervention.
Ages Eligible for Study: | 20 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Introduction to the study of Cura-100 
  |
Study ID Numbers: | CURA-07-10 |
First Received: | March 30, 2007 |
Last Updated: | March 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00455208 |
Health Authority: | United States: Food and Drug Administration |
|
|
|